Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety

PurposeAlthough pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined.MethodsA...

Полное описание

Библиографические подробности
Главные авторы: Yujia Zhai, Dai Yuan, Xueling Ge, Shunfeng Hu, Peipei Li, Xiaosheng Fang, Ying Li, Xiangxiang Zhou, Xin Wang
Формат: Статья
Язык:English
Опубликовано: Frontiers Media S.A. 2021-03-01
Серии:Frontiers in Oncology
Предметы:
pegylated liposomal doxorubicin
multiple myeloma
efficacy
survival
toxicity
Online-ссылка:https://www.frontiersin.org/articles/10.3389/fonc.2021.597453/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.597453/full

Схожие документы